Novel approaches to tuberculosis prevention: DNA vaccines

References

• Glaziou P, Falzon D, Floyd K, Raviglione M. Global epidemiology of tuberculosis. Semin Respir Crit Care Med 2013;34:3–16.
   PubMed Web of Science ®Google Scholar
• Moss AR, Alland D, Telzak E, Hewlett D Jr, Sharp V, Chiliade P, et al. A city-wide outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in New York. Int J Tuberc Lung Dis 1997;1:115–21.
   PubMed Web of Science ®Google Scholar
• Jarand J, Shean K, O’Donnell M, Loveday M, Kvasnovsky C, Van der Walt M, et al. Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Trop Med Int Health 2010;15:1179–84.
   PubMedGoogle Scholar
• Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, et al. Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PLoS One 2012;7:e31786.
   Google Scholar
• Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009;136:420–5.
   PubMed Web of Science ®Google Scholar
• Brewer TF. Preventing tuberculosis with bacillus Calmette–Guérin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000;31(Suppl 3):S64–7.
   Google Scholar
• Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339–45.
   PubMed Web of Science ®Google Scholar
• Rook GA, Dheda K, Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?Vaccine 2005;23:2115–20.
   PubMed Web of Science ®Google Scholar
• Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go?PLoS Pathog 2012;8:e1002607.
   PubMed Web of Science ®Google Scholar
• Romano M, Aryan E, Korf H, Bruffaerts N, Franken CL, Ottenhoff TH, et al. Potential of Mycobacterium tuberculosis resuscitation-promoting factors as antigens in novel tuberculosis sub-unit vaccines. Microbes Infect 2012;14:86–95.
   PubMed Web of Science ®Google Scholar
• Acosta A, Norazmi MN, Hernandez-Pando R, Alvarez N, Borrero R, Infante JF, et al. The importance of animal models in tuberculosis vaccine development. The Malaysian Journal of Medical Sciences 2011;18:5–12.
   PubMedGoogle Scholar
• Sambandamurthy VK, Jacobs WR Jr. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 2005;7:955–61.
   PubMed Web of Science ®Google Scholar
• Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis 2005;85:29–38.
   PubMed Web of Science ®Google Scholar
• Kondratieva T, Rubakova E, Kana BD, Biketov S, Potapov V, Kaprelyants A, Apt A. Mycobacterium tuberculosis attenuated by multiple deletions of rpf genes effectively protects mice against TB infection. Tuberculosis 2011;91:219–23.
   PubMed Web of Science ®Google Scholar
• Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, Penn E, et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009;27:4412–23.
   PubMed Web of Science ®Google Scholar
• Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, et al. A new recombinant bacille Calmette–Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008;198:1491–501.
   PubMed Web of Science ®Google Scholar
• Pal PG, Horwitz MA. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun 1992;60:4781–92.
   PubMed Web of Science ®Google Scholar
• Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 2001;69:2773–8.
   PubMed Web of Science ®Google Scholar
• Denis O, Tanghe A, Palfliet K, Jurion F, van den Berg TP, Vanonckelen A, et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4 + and CD8 + T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun 1998;66:1527–33.
   PubMed Web of Science ®Google Scholar
• Cervantes-Villagrana AR, Hernandez-Pando R, Biragyn A, Castaneda-Delgado J, Bodogai M, Martinez-Fierro M, et al. Prime-boost BCG vaccination with DNA vaccines based in beta-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model. Vaccine 2013;31:676–84.
   PubMed Web of Science ®Google Scholar
• Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005;23:2132–5.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine 2006;24:1191–204.
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+ IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. Vaccine 2007;25:2990–3.
   PubMed Web of Science ®Google Scholar
• Biragyn A. Defensins—non-antibiotic use for vaccine development. Curr Protein Pept Sci 2005;6:53–60.
   PubMed Web of Science ®Google Scholar
• Garg S, Oran A, Wajchman J, Sasaki S, Maris CH, Kapp JA, Jacob J. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol 2003;4:907–12.
   PubMedGoogle Scholar
• Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ. Molecular and cellular mechanisms of DNA vaccines. Hum Vaccin 2008;4:453–6.
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004;114:1241–4.
   PubMed Web of Science ®Google Scholar
• Babiuk S, Mookherjee N, Pontarollo R, Griebel P, van Drunen Littel-van den Hurk S, Hecker R, Babiuk L. TLR9−/− and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology 2004;113:114–20.
   PubMed Web of Science ®Google Scholar
• Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med 1996;2:893–8.
   PubMed Web of Science ®Google Scholar
• Goncalves ED, Bonato VL, da Fonseca DM, Soares EG, Brandao IT, Soares AP, et al. Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming. Genet Vaccines Ther 2007;5:7.
   PubMedGoogle Scholar
• Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999;67:1702–7.
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Liu MA, Montgomery DL, Yawman AM, Deck RR, DeWitt CM, et al. Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination. Vaccine 1997;15:792–4.
   PubMedGoogle Scholar
• Tanghe A, D’Souza S, Rosseels V, Denis O, Ottenhoff TH, Dalemans W, et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 2001;69:3041–7.
   PubMed Web of Science ®Google Scholar
• Wang QM, Sun SH, Hu ZL, Yin M, Xiao CJ, Zhang JC. Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting. Vaccine 2004;22:3622–7.
   PubMed Web of Science ®Google Scholar
• Skeiky YA, Ovendale PJ, Jen S, Alderson MR, Dillon DC, Smith S, et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol 2000; 165:7140–9.
   PubMed Web of Science ®Google Scholar
• Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999;400:269–71.
   PubMed Web of Science ®Google Scholar
• Roche PW, Peake PW, Billman-Jacobe H, Doran T, Britton WJ. T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of Mycobacterium bovis. Infect Immun 1994;62:5319–26.
   PubMedGoogle Scholar
• Zhang X, Divangahi M, Ngai P, Santosuosso M, Millar J, Zganiacz A, et al. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine 2007;25:1342–52.
   PubMed Web of Science ®Google Scholar
• Dou J, Wang Y, Yu F, Yang H, Wang J, He X, et al. Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting. Int J Immunogenet 2012;39:183–90.
   PubMed Web of Science ®Google Scholar
• Hu D, Wu J, Zhang R, Chen L. T-bet acts as a powerful adjuvant in Ag85B DNA-based vaccination against tuberculosis. Mol Med Rep 2012;6:139–44.
   PubMed Web of Science ®Google Scholar
• Wozniak TM, Ryan AA, Triccas JA, Britton WJ. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect Immun 2006;74:557–65.
   PubMed Web of Science ®Google Scholar
• Satkauskas S, Bureau MF, Mahfoudi A, Mir LM. Slow accumulation of plasmid in muscle cells: supporting evidence for a mechanism of DNA uptake by receptor-mediated endocytosis. Mol Ther 2001;4:317–23.
   PubMed Web of Science ®Google Scholar
• Jeon BY, Eoh H, Ha SJ, Bang H, Kim SC, Sung YC, Cho SN. Co-immunization of plasmid DNA encoding IL-12 and IL-18 with bacillus Calmette–Guérin vaccine against progressive tuberculosis. Yonsei Med J 2011;52:1008–15.
   PubMed Web of Science ®Google Scholar
• Wang J, Snider DP, Hewlett BR, Lukacs NW, Gauldie J, Liang H, et al. Transgenic expression of granulocyte- macrophage colony-stimulating factor induces the differentiation and activation of a novel dendritic cell population in the lung. Blood 2000;95:2337–45.
   PubMed Web of Science ®Google Scholar
• Fyall KM, Fong AM, Rao SB, Ibrahim JG, Waxweiler WT, Thomas NE. The TBX21 transcription factor T-1993C polymorphism is associated with decreased IFN-gamma and IL-4 production by primary human lymphocytes. Hum Immunol 2012;73:673–6.
   PubMedGoogle Scholar
• Chaparas SD. Immunity in tuberculosis. Bull World Health Organ 1982;60:447–62.
   PubMedGoogle Scholar
• Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002;298:1025–9.
   PubMed Web of Science ®Google Scholar
• Biragyn A, Coscia M, Nagashima K, Sanford M, Young HA, Olkhanud P. Murine beta-defensin 2 promotes TLR-4/MyD88-mediated and NF-kappaB-dependent atypical death of APCs via activation of TNFR2. J Leukoc Biol 2008;83: 998–1008.
   PubMed Web of Science ®Google Scholar
• Biragyn A, Surenhu M, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001;167:6644–53.
   PubMed Web of Science ®Google Scholar
• Marquina-Castillo B, Garcia-Garcia L, Ponce-de-Leon A, Jimenez-Corona ME, Bobadilla-Del Valle M, Cano-Arellano B, et al. Virulence, immunopathology and transmissibility of selected strains of Mycobacterium tuberculosis in a murine model. Immunology 2009;128:123–33.
   PubMed Web of Science ®Google Scholar
• Hernandez-Pando R, Marquina-Castillo B, Barrios-Payan J, Mata-Espinosa D. Use of mouse models to study the variability in virulence associated with specific genotypic lineages of Mycobacterium tuberculosis. Infect Genet Evol 2012;12: 725–31.
   PubMed Web of Science ®Google Scholar
• Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012;4:155ra38.
   Google Scholar
• Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother 2012;61:2161–70.
   PubMed Web of Science ®Google Scholar
• Vardas E, Stanescu I, Leinonen M, Ellefsen K, Pantaleo G, Valtavaara M, et al. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(R)- Multi-HIVB, in untreated HIV-1 infected subjects. Vaccine 2012;30:4046–54.
   PubMed Web of Science ®Google Scholar
• Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997;8:2133–41.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for assuring the quality and nonclinical safety evaluation of DNA vaccines. World Health Organ Tech Rep Ser 2007; Annex 1:
   Google Scholar